BioLineRx Ltd. Files Form 6-K Reporting Press Release
Ticker: BLRX · Form: 6-K · Filed: Apr 17, 2024 · CIK: 1498403
Sentiment: neutral
Topics: press-release, filing
TL;DR
BioLineRx dropped a 6-K on 4/17, likely with news. Check the exhibits.
AI Summary
BioLineRx Ltd. filed a Form 6-K on April 17, 2024, to report the issuance of a press release. The filing itself does not contain the details of the press release, only that it was issued on this date.
Why It Matters
This filing indicates that BioLineRx Ltd. has made a public announcement, the details of which are likely to be material to investors.
Risk Assessment
Risk Level: low — The filing is a routine report of a press release issuance and does not contain new financial or operational information itself.
Key Players & Entities
- BioLineRx Ltd. (company) — Registrant
- April 17, 2024 (date) — Date of press release issuance
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report the issuance of a press release by BioLineRx Ltd. on April 17, 2024.
When was the press release issued by BioLineRx Ltd.?
The press release was issued on April 17, 2024.
Does this Form 6-K contain the full text of the press release?
No, this Form 6-K filing states that the press release is filed as Exhibit 1, implying the full text is within the exhibits, not the main body of the 6-K.
What is the principal executive office address for BioLineRx Ltd.?
The principal executive offices are located at 2 HaMa'ayan Street, Modi'in 7177871, Israel.
Under which act is BioLineRx Ltd. filing this report?
BioLineRx Ltd. is filing this report pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Filing Stats: 150 words · 1 min read · ~1 pages · Grade level 10 · Accepted 2024-04-17 07:12:25
Filing Documents
- zk2431304.htm (6-K) — 9KB
- exhibit_1.htm (EX-99.1) — 35KB
- image00001.jpg (GRAPHIC) — 402KB
- 0001178913-24-001347.txt ( ) — 598KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant's name into English) 2 HaMa'ayan Street Modi'in 7177871, Israel (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F On April 17, 2024, the registrant issued the press release which is filed as Exhibit 1 to this Report on Form 6-K. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioLineRx Ltd. By: /s/ Philip A. Serlin Philip A. Serlin Chief Executive Officer Dated: April 17, 2024